Evidence map›Paper›PMID 27097599›Full record

ArticleEndocrine connections2016

The HABP2 G534E polymorphism does not increase nonmedullary thyroid cancer risk in Hispanics.

Mabel E Bohórquez, Ana P Estrada, Jacob Stultz, Ruta Sahasrabudhe, John Williamson, Paul Lott, Carlos S Duque, Jorge Donado, Gilbert Mateus, Fernando Bolaños and 3 more

Open access · goldAbstract read
In one paragraph

Article in Endocrine connections, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 18 citations in OpenAlex.

  1. Genetic susceptibility to hereditary non-medullary thyroid cancer.Hereditary cancer in clinical practice · 2022
    Review
  2. Review
  3. Article
  4. The p.G534E variant ofOncotarget · 2017
    Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 2 countries.

Mabel E BohórquezGrupo de CitogenéticaFilogenia y Evolución de Poblaciones, Facultad de Ciencias y Facultad de Ciencias de la Salud, Universidad del Tolima, Ibagué, Colombia.
Ana P EstradaGrupo de CitogenéticaFilogenia y Evolución de Poblaciones, Facultad de Ciencias y Facultad de Ciencias de la Salud, Universidad del Tolima, Ibagué, Colombia.
Jacob StultzGenome Center and Department of Biochemistry and Molecular MedicineSchool of Medicine, University of California, Davis, California, USA.
Ruta SahasrabudheGenome Center and Department of Biochemistry and Molecular MedicineSchool of Medicine, University of California, Davis, California, USA.
John WilliamsonGenome Center and Department of Biochemistry and Molecular MedicineSchool of Medicine, University of California, Davis, California, USA.
Paul LottGenome Center and Department of Biochemistry and Molecular MedicineSchool of Medicine, University of California, Davis, California, USA.
Carlos S DuqueHospital Pablo Tobón UribeMedellín, Colombia.
Jorge DonadoHospital Pablo Tobón UribeMedellín, Colombia.
Gilbert MateusHospital Federico Lleras AcostaIbagué, Colombia.
Fernando BolañosHospital Hernando Moncaleano PerdomoNeiva, Colombia.
Alejandro VélezHospital Pablo Tobón UribeMedellín, Colombia.
Magdalena EcheverryGrupo de CitogenéticaFilogenia y Evolución de Poblaciones, Facultad de Ciencias y Facultad de Ciencias de la Salud, Universidad del Tolima, Ibagué, Colombia.
Luis G Carvajal-CarmonaGrupo de CitogenéticaFilogenia y Evolución de Poblaciones, Facultad de Ciencias y Facultad de Ciencias de la Salud, Universidad del Tolima, Ibagué, Colombia Genome Center and Department of Biochemistry and Molecular MedicineSchool of Medicine, University of California, Davis, California, USA Fundación de Genética y GenómicaMedellín, Colombia lgcarvajal@ucdavis.edu.
University of California, Davis · USHospital Pablo Tobon Uribe · COUniversity of Tolima · COCentro Dermatológico Federico Lleras Acosta · COHospital Universitario de Neiva · CO

Funding

UC Davis Paul Calabresi K12 Clinical Oncology Research Career Development ProgramK12CA138464 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI BIRKELAND, ANDREW CHARLES, LARA, PRIMO N. · 2011 to 2025
$11.4M
NCI NIH HHS K12 CA138464
6 · The paper itself

Abstract

Familial nonmedullary thyroid cancer (NMTC) has not been clearly linked to causal germline variants, despite the large role that genetic factors play in risk. Recently, HABP2 G534E (rs7080536A) has been implicated as a causal variant in NMTC. We have previously shown that the HABP2 G534E variant is not associated with TC risk in patients from the British Isles. Hispanics are the largest and the youngest minority in the United States and NMTC is now the second most common malignancy in women from this population. In order to determine if the HABP2 G534E variant played a role in NMTC risk among Hispanic populations, we analyzed 281 cases and 1105 population-matched controls from a multicenter study in Colombia, evaluating the association through logistic regression. We found that the HABP2 G534E variant was not significantly associated with NMTC risk (P=0.843) in this Hispanic group. We also stratified available clinical data by multiple available clinicopathological variables and further analyzed the effect of HABP2 on NMTC presentation. However, we failed to detect associations between HABP2 G534E and NMTC risk, regardless of disease presentation (P≥0.273 for all cases). Therefore, without any significant associations between the HABP2 G534E variant and NMTC risk, we conclude that the variant is not causal of NMTC in this Hispanic population.

Indexed as

G534EHABP2Hispanicsthyroid cancer

Identifiers

PMID27097599
PMCPMC5002962
OpenAlexW2408534344

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.